Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 323 publications.

Msihid J, Joulain F, Hawe E, Burgess B, Thomas RB, Tilton ST. Assessing the relationship between EQ-5D-3L index scores and disease-specific patient-reported outcome measures in eosinophilic oesophagitis. Poster to be given at the ISPOR Europe 2024; November 18, 2024. Barcelona, Spaine.

Keogh KA, Dolin P, Kielar D, Shavit A, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen SY. Pulmonary and cardiovascular involvement and persistent damage in eosinophilic granulomatosis with polyangiitis: a retrospective analysis of US health insurance claims data. Poster presented at the CHEST 2024; October 9, 2024. Boston, MA. [abstract] Chest. 2024 Oct; 166(4, Suppl):A5373-A57.

La E, Sweeney C, Davenport E, Bunniran S. Work loss associated with adult vaccinations in pharmacy and healthcare professional office settings in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S138. doi: 10.1016/j.jval.2024.03.738

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with diabetes in the United States. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):1045.

Shavit A, Dolin P, Kielar D, Keogh KA, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen SY. Pulmonary involvement and persistent pulmonary damage in eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the American Thoracic Society (ATS) 2024 Meeting; May 19, 2024. San Diego, CA.

La E, Singer D, Graham J, Grace M, Molnar D. Modeled public health impact of increasing respiratory syncytial virus vaccination coverage among adults Aged ≥ 60 years in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024.

La E, Sweeney C, Davenport E, Bunniran S. Pharmacies as convenient adult vaccination settings in the United States: patient experiences from a survey of recently vaccinated adults. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024. Virtual.

La E, Sweeney C, Davenport E, Bunniran S. Patient experiences with respiratory syncytial virus vaccination during the first season of vaccine availability: results from a survey of recently vaccinated older adults in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024. Virtual.

Molnar D, La EM, Verelst F, Poston S, Graham J, Van Bellinghen LA, Curran D. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Infect Dis Ther. 2024 Apr;13(4):827-44. doi: 10.1007/s40121-024-00939-w

Bali V, Schelfhout J, Sher MR, Tripathi Peters A, Patel GB, Mayorga M, Goss D, Romano (DeMuro) C. Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis. Ther Adv Respir Dis. 2024 Mar 19;18:175346662. doi: 10.1177/17534666241236025

La E, Verelst F, Curran D, Poston S, Graham J, Molnar D. Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults AGED ≥60 years in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled burden of RSV in adults aged 50-59 years with chronic cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled impact of adjuvanted RSVPREF3 vaccination on RSV-related health outcomes in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.

Dolin P, Kielar D, Shavit A, Koegh K, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen S. Comorbidities in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 23, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB53.

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Healthcare resource utilization and costs in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 25, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB206.

Ghaswalla P, Carrico J, Hicks KA. The annual economic burden of respiratory syncytial virus in adults in the United States. Presented at the 2024 Biomedical Advanced Research and Development Authority George Risi Memorial Journal Club; January 22, 2024.

Martin Nguyen A, La Rosa C, Cornell AG, Sher MR, Bernstein JA, Birring SS, DeMuro Romano C, Mayorga M, Milien M, Ervin C. Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study. Ther Adv Respir Dis. 2024 Jan;18:175346662. doi: 10.1177/17534666241274261

La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2023 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796

Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S. Clinical burden of patients with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S549-50. doi: 10.1016/j.jval.2023.09.2953

Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S. Economic burden of patients in the United States with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplment):S553. doi: 10.1016/j.jval.2023.09.2970

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Diagnosis pathways in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the American College of Rheumatology (ACR) Convergence 2023; November 13, 2023. San Diego, CA. Previously presented at the Eastern Pulmonary Conference.

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Treatment patterns for eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the American College of Rheumatology (ACR) Convergence 2023; November 13, 2023. San Diego, CA.

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Disease burden or eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the American College of Rheumatology (ACR) Convergence 2023; November 13, 2023. San Diego, CA.

Williams V, Romano (DeMuro) C, Clark M, Korver D, Williams N, Goss D, Naujoks C, Marvel J. Psychometric evaluation of an electronic Asthma Symptom Diary for young children. J Patient Rep Outcomes. 2023 Oct 30;7(1):105. doi: 10.1186/s41687-023-00647-y

Dolin P, Kielar D, Shavit A, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen SY. Comparison of healthcare resource utilization and costs in patients with and without eosinophilic granulomatosis with polyangiitis: a retrospective analysis of US health insurance claims data. Poster presented at the 2023 Eastern Pulmonary Conference; September 21, 2023. West Palm Beach, FL.

Dolin P, Kielar D, Shavit A, Keogh KA, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen SY. Diagnosis pathways in patients with eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective analysis of US health insurance claims data. Poster presented at the 2023 Eastern Pulmonary Conference; September 21, 2023. West Palm Beach, FL.

Bell CF, Ajmera M, Meyers J. Retrospective analysis of the burden of illness of eosinophilic granulomatosis with polyangiitis (EGPA) versus asthma in commercially insured US patients. Cureus J Med Science. 2023 Jul 21;15(7):e42241. doi: 10.7759/cureus.42241

La EM, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Knowledge, attitudes, and perceptions of respiratory syncytial virus (RSV) among U.S. adults with diabetes. Poster presented at the ADA 2023 Conference; June 24, 2023. San Diego, CA. [abstract] Diabetes. 2023 Jun 20; 72(Suppl 1). doi: 10.2337/db23-524-P

Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J. Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S172. doi: 10.1016/j.jval.2023.03.927

Verelst F, La E, Graham J, Molnar D. Leveraging time-use data to estimate market and non-market productivity losses due to respiratory syncytial virus (RSV) disease among adults aged ≥60 years in the United States (US). Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S120. doi: 10.1016/j.jval.2023.03.632

La E, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Respiratory syncytial virus (RSV) knowledge, attitudes, and perceptions among adults with chronic pulmonary conditions in the US. Poster presented at the ATS American Thoracic Society 2023; May 19, 2023. Washington, DC.

Khan AH, Kosa K, De Prado Gomez L, Whalley D, Kamat S, Clark M. Content validation of patient-reported sleep measures and development of a conceptual model of sleep disturbance in patients with moderate-to-severe, uncontrolled asthma. Patient Relat Outcome Meas. 2023 Mar 23;14:57-71. doi: 10.2147/PROM.S392666

Molnar D, La E, Verelst F, Curran D, Poston S, Graham J. Modeling the clinical and economic burden of respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Talbird S, Cook C, DeMartino J, Hernandez-Pastor L, Krishnarajah G. Projected impact of RSV vaccine in US adults ≥ 60 years of age. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Colosia A, Costello J, McQuarrie K, Kato K, Bertzos K. Systematic literature review of the signs and symptoms of respiratory syncytial virus. Influenza Other Respi Viruses. 2023 Feb 5;17(2):e13100. doi: 10.1111/irv.13100

Williams V, Romano (DeMuro) C, Clark M, Goss D, Naujoks C, Marvel J. Psychometric evaluation of a new electronic pediatric asthma symptom diary. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S428. doi: 10.1016/j.jval.2022.09.2130

Herring W, Shen Q, Zhang Y, Martin A, Otiker T, Zhang W. The relationship between Asthma Control Questionnaire scores and exacerbation risk, resource utilization, and utility values: an analysis from the CAPTAIN trial. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S36. doi: 10.1016/j.jval.2022.09.174

Bali V, Schelfhout J, Sher M, Peters A, Patel G, Mayorga M, (DeMuro) Romano C. Patient-reported symptoms, impacts, and treatment preferences in refractory or unexplained chronic cough: a qualitative study. Poster presented at the 2022 Advancing Allergy & Immunology Care (ACAAI) Annual Scientific Meeting; November 13, 2022. Louisville, KY.

La E, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among older adults in the United States. Poster presented at the 12th International RSV Symposium; September 29, 2022. Belfast, Ireland.

Costello J, Colosia A, Bertzos K, McQuarrie K. Systematic literature review of the signs and symptoms of respiratory syncytial virus in high-risk adults and immunocompromised populations. Poster presented at the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) 2022 Conference; September 26, 2022. Belfast, United Kingdom.

Costello J, Colosia A, Kato K, Bertzos K, McQuarrie K. Systematic literature review of the signs and symptoms of respiratory syncytial virus in young children. Poster presented at the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) 2022 Conference; September 26, 2022. Belfast, United Kingdom.

Marvel J, Goransson O, Clark M, Romano (DeMuro) C, Olayinka-Amao O, Whalley D, Crawford R, Brindicci C, Garg K, Kordy K, Everhard F, Patalano F, Roesler Z, Landles R, Naujoks C, Gutzwiller FS. Interactive tablet application for self-report of asthma symptoms and impacts in young children. Poster presented at the ERS International Congress 2022; September 6, 2022. Barcelona, Spain. [abstract] Eur Respir J. 2022 Sep 4; 60(Suppl 66):2127. doi: 10.1183/13993003.congress-2022.2127

Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-33. doi: 10.2147/COPD.S363997

Rebordosa C, Farkas DK, Montonen J, Laugesen K, Voss F, Aguado J, Bothner U, Rothman KJ, Zint K, Mines DI, Ehrenstein V. Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists. Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):827-39. doi: 10.1002/pds.5432

Saigi-Morgui N, Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud SZ, McMahon P, Perez-Gutthann S, Rivero-Ferrer E. Acute myocardial infarction, stroke, and MACE in COPD patients treated with aclidinium and other inhaled bronchodilators. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2

Clark M, Romano C, Olayinka-Amao O, Whalley D, Crawford R, Pathak P, Brindicci C, Garg K, Kordy K, Everhard F, Patalano F, Roesler Z, Sutton T, Goransson O, Landles R, Naujoks C, Marvel J, Keininger DL. Development and content validation of a self-completed, electronic Pediatric Asthma Symptom Diary. J Patient Rep Outcomes. 2022 Mar 20;6(1):25. doi: 10.1186/s41687-022-00432-3

Simpson EL, de Bruin-Weller M, Bansal A, Chen Z, Nelson L, Whalley D, Prescilla R, Guillemin I, Delevry D. Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther. 2021 Aug;11(4):1415-22. doi: 10.1007/s13555-021-00543-7

Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-75. doi: 10.2147/COPD.S301624